AbbVie Inc. Average Days of Payables

Average Days of Payables of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Payables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Payables for 2019 was 580.55 (a 2.89% increase from previous year)
  • Annual Average Days of Payables for 2018 was 564.24 (a 6.45% increase from previous year)
  • Annual Average Days of Payables for 2017 was 530.03 (a -9.7% decrease from previous year)
  • Twelve month Average Days of Payables ending June 29, 2020 was 734.46 (a 21.71% increase compared to previous quarter)
  • Twelve month trailing Average Days of Payables increased by 22.79% year-over-year
Trailing Average Days of Payables for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
734.46 603.46 580.55 598.15
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Payables of AbbVie Inc.

Most recent Average Days of Payablesof ABBV including historical data for past 10 years.

Interactive Chart of Average Days of Payables of AbbVie Inc.

AbbVie Inc. Average Days of Payables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 580.55
2018 564.24
2017 530.03
2016 586.99
2015 686.44
2014 573.48
2013 513.76
2012 464.27
2011 462.72
2010 30.33
2009 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.